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Recent linkage analyses of nondiabetic African-American
patients with focal segmental glomerulosclerosis (FSGS) have
identifiedMYH9, encoding nonmuscle myosin heavy chain IIA
(NMMHC-IIA), as a gene having a critical role in this disease.
Abnormalities of theMYH9 locus also underlie rare autosomal
dominant diseases such as May–Hegglin anomaly, and
Sebastian, Epstein (EPS), and Fechtner (FTNS) syndromes that
are characterized by macrothrombocytopenia and
cytoplasmic inclusion bodies in granulocytes. Among these
diseases, patients with EPS or FTNS develop progressive
nephritis and hearing disability. We analyzed clinical features
and pathophysiological findings of nine EPS–FTNS patients
with MYH9 mutations at the R702 codon hot spot. Most
developed proteinuria and/or hematuria in early infancy and
had a rapid progression of renal impairment during
adolescence. Renal histopathological findings in one patient
showed changes compatible with FSGS. The intensity of
immunostaining for NMMHC-IIA in podocytes was decreased
in this patient compared with control patients. Thus, MYH9
R702 mutations display a strict genotype–phenotype
correlation, and lead to the rapid deterioration of podocyte
structure. Our results highlight the critical role of NMMHC-IIA
in the development of FSGS.
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May–Hegglin anomaly and Sebastian syndrome are rare
autosomal dominant disorders characterized by thrombocy-
topenia, giant platelets, and granulocyte cytoplasmic inclu-
sion bodies called Do¨hle body-like inclusion bodies.1 There
are two related disorders, namely, Fechtner syndrome (FTNS)
and Epstein syndrome (EPS), in which progressive hearing
disability and nephritis are observed.1 In FTNS, cataract is
also present. Recently, MYH9, a gene encoding nonmuscle
myosin heavy chain IIA (NMMHC-IIA), has been identified
as the causative gene for these four disorders.2–5 Several
mutations in MYH9 have been identified, and the existence of
mutational hot spots in MYH9, that is, codons R702, R1165,
D1424, E1841, and R1933, has been reported.6–9
As mutations in a single gene cause four distinct disorders,
a novel nomenclature, MYH9 disorders, has been pro-
posed.6,8,10 However, the mechanisms by which mutations
in a single gene cause a variety of phenotypes remain to
be elucidated.1 Certain mutations in MYH9 have been
associated with the development of renal phenotypes, and
R702 mutation is one of these.7–10 Nevertheless, detailed
information on renal manifestations, renal histology, and
prognosis has been lacking.
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In addition to macrothrombocytopenic diseases due to
MYH9 mutations, a significant association between the
development of idiopathic focal segmental glomerulosclerosis
(FSGS) or end-stage renal disease (ESRD) in African-
American individuals and single-nucleotide polymorphisms
in MYH9 was identified in 2008.11,12 This finding shows that
NMMHC-IIA is responsible for not only EPS–FTNS, but also
FSGS. Structural or functional abnormalities of NMMHC-
IIA are considered to be critical in the development of FSGS
in the African-American population.
In this study, we analyzed nine cases with R702 mutation
in MYH9. Most cases with R702 mutation in MYH9 develop
nephritis characterized by proteinuria and/or hematuria in
early infancy, and the deterioration of renal function
accelerates in early adolescence. Hearing disability also
manifests in early infancy and progresses to deafness at
approximately 30 years of age. Findings of a serial renal
biopsy in one case indicated that the pathological feature
underlying this progressive nephritis is FSGS.
RESULTS
Clinical presentation and MYH9 mutations
The clinical backgrounds of each case are summarized in
Table 1. The age at the latest examination ranges from 4 to
33 years. Most of the cases were diagnosed as having
idiopathic thrombocytopenic purpura at first presentation.
Genetic analysis revealed R702H mutation in case 1 and
R702C mutation in the remaining 8 cases. All the R702
mutations identified in this study were de novo mutations.
No disease-related family histories were noted.
Urinary abnormalities and development of renal dysfunction
The renal manifestations of nine cases are described in
Table 1. Except for case 1, all the other cases developed
proteinuria and/or hematuria before 12 years of age. Case 2
developed significant proteinuria (1þ ; urine protein/
gCr¼ 310 mg/g creatinine (Cr)) as early as 2 years and
7 months of age. It is notable that four cases over 15 years old
developed ESRD between 15 and 20 years of age. Distinct
from another progressive hereditary nephritis, that is,
Alport’s syndrome, none of the cases showed macroscopic
hematuria at presentation. For cases 6, 7, 8, and 9 who
developed ESRD, their serum Cr levels are plotted in Figure 1.
Each case progressed to ESRD shortly after the serum Cr level
exceeded 1.0 mg/dl. The clinical status at the latest evaluation
is described in Table 1 along with age at final evaluation.
Extrarenal manifestations
Among these cases, only case 1 showed cataract (Table 2). A
hearing disability was observed in most of the cases by
approximately 5 years of age, which progressed rapidly. Over
30 years old, all of the cases in this study became deaf.
Renal histopathological analysis of case 6
Light and electron microscopy findings of serial renal
biopsies of specimens from case 6 are shown in Figure 2.
The first biopsy was performed at 9 years of age by surgical
operation, when the serum Cr level was 0.4 mg/dl. Twenty-
four glomeruli were obtained, and mild mesangial cell
proliferations and expansion were observed in most glomer-
uli (Figure 2a). Sclerotic lesions were not observed in any
glomeruli, and tubulointerstitial changes were minimal.
Immunofluorescence studies using immunoglobulins G, A,
M, and C1q, C3, and C4 antibodies showed negative or no
significant findings. Electron microscopy of these specimens
revealed focal lesions of podocyte foot process effacement
(indicated by an arrow in Figure 2c). Focal glomerular
basement membrane (GBM) thickening lesions were
observed (up to 1000–1500 nm in diameter), whereas most
GBM show normal appearance (thickness ranges from 300 to
400 nm). The other GBM abnormalities, such as splitting,
attenuation, or reticulation, were not observed. The second
biopsy was performed by needle biopsy when the case was 11
years and 9 months of age. Only four glomeruli were
obtained; one glomerulus showed global sclerosis, and two of
the remaining three glomeruli showed segmental sclerosis.
Table 1 | Clinical backgrounds and renal manifestations in patients with R702 mutation in MYH9
First
Age and urinalysis findings when
urine abnormalities were first noted Age at latest evaluation and each clinical status
Case
no. Sex
Ethnic
background
MYH9
mutation
clinical
diagnosis Age Proteinuria Hematuria Age
Clinical
status
Age at CKD
5 onset Proteinuria Hematuria
1 F Japanese R702H ITP () () 4y11m w.n.l () ()
2 F Japanese R702C MHA 2y7m (1+) () 4y2m CKD stage 1 () ()
3 F Chinese R702C ITP 6y8m () (1+) 6y8m CKD stage 1 () (1+)
4 M Japanese R702C ITP 5y8m (2+) (3+) 12y3m CKD stage 1 (3+) (3+)
5 M Japanese R702C ITP 11y8m (+) (+/) 11y8m CKD stage 1 (+) (+/)
6 F Japanese R702C ITP 8y8m (1+) (1+) 21y3m Transplant 15y
7 M Japanese R702C MHA 9y (1+) (1+) 20y7m Transplant 17y
8 F Japanese R702C ITP Unknown Unknown 33y PD/HD 16y
9 F Japanese R702C ITP 5y8m (+/) Unknown 32y Transplant 20y
Abbreviations: HD, hemodialysis; HPF, high power fields; ITP, idiopathic thrombocytopenic purpura; MHA, May–Hegglin anomaly; m, month; PD, peritoneal dialysis; y, year.
In the urinalysis, stages of proteinuria and hematuria were defined as follows:
Proteinuria: +/, 15mg/dl; +, 30mg/dl; 2+, 100mg/dl; 3+. 300mg/dl or over 300mg/dl.
Hematuria: +/, RBC B5/HPF; 1+, 5-10/HPF; 2+, 10B50/HPF; 3+, 450-100/HPF.
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The glomeruli were not enlarged. Interstitial fibrosis, cellular
infiltration, and tubular atrophy were observed around the
impaired glomeruli. At the time of the second renal biopsy,
the serum Cr level was 0.6 mg/dl, and the estimated
glomerular filtrate rate calculated by Schwartz’s formula
was 107 ml/min per 1.73 m2. The findings of the second
biopsy of case 6 are compatible with the diagnosis of FSGS.
Considering an almost normal glomerular filtrate rate at the
time of the second renal biopsy, absence of enlarged
glomeruli in the kidney specimen, and the subsequent rapid
progression to ESRD in this patient, focal segmental sclerosis
is considered to be the primary lesion due to MYH9 mutation
rather than a phenomenon secondary to nephron mass
reduction.
Immunohistochemical analyses of NMMHC-IIA in control and
case 6 kidney samples
Figure 3 shows the immunostaining data of NMMHC-IIA in
the glomerulus in normal control and case 6 kidney samples.
In the glomeruli of the control sample, the intensity of
NMMHC-IIA immunostaining is very strong in podocytes
(Figure 3a and b). In the first biopsy specimen from case 6,
the intensity of immunostaining of NMMHC-IIA is already
significantly decreased (Figure 3c and d). The second biopsy
specimen from case 6 (Figure 3e and f) also shows a
decreased NMMHC-IIA immunostaining intensity.
In the normal kidney sample, NMMHC-IIA is also
expressed in renal tubular cells, particularly those of the distal
tubule, Henle’s loop, and proximal tubular cells (Figure 4a-d).
Endothelial cells of interlobular arteries and arterioles, and
peritubular capillaries also express NMMHC-IIA (Figure 4a-c).
In case 6, NMMHC-IIA expression in renal tubular cells and
endothelial cells did not change significantly (Figure 4e and f).
NMMHC-IIA distribution in peripheral blood neutrophils
The NMMHC-IIA distribution pattern in peripheral blood
neutrophils was examined by immunofluorescence analysis.
In normal blood neutrophils, NMMHC-IIA distributes
diffusely in the cytoplasm (Figure 5, control 1, 2, and 3).
In all the cases with MYH9 R702 mutations, NMMHC-IIA
was condensed and localized in the peripheral region of
neutrophils (Figure 5, cases 1–9; condensation of NMMHC-
IIA is indicated by an arrowhead). This granular pattern
(type II) was observed in neutrophils from all the cases with
R702 mutations (Figure 5 and Table 2, see Methods and
Discussion sections for the definition of NMMHC-IIA
distribution patterns in neutrophils).
Effect of ARB/ACEI on urinary abnormalities and renal
function in three cases
Three cases, namely cases 2, 4, and 7, were treated with
angiotensin receptor blockers (ARB) and/or angiotensin-
converting enzyme inhibitors (ACEIs) for progressive ne-
phritis. Figure 6 shows the effect of ARB/ACEI on urinary
protein level in case 2. The urinary protein level evaluated in
terms of urine protein/Cr was decreased from 500–700 mg/
gCr to approximately 100 mg/gCr by administration of 20 mg
of valsartan (Figure 6). In cases 4 and 7, the effect of ARB/
ACEI was not very conclusive (data not shown). In case 4,
other drugs such as cyclosporine A were used simultaneously;
therefore, the effect of only ARB/ACEI could not be
determined. In case 7, the effect of ARB/ACEI was transient.
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Figure 1 |Rapid progression of renal dysfunction in cases 6, 7,
8, and 9. Serum Cr levels (mg/dl) of cases 6, 7, 8, and 9 are
plotted. The rapid deterioration of renal function is apparent in
these cases. Each case progressed to end-stage renal disease
shortly after Cr levels exceeded 1.0mg/dl.
A. 9 year
(PAS stain)
B. 11 year
(PAS stain)
C. 9 year
(EM)
Figure 2 |Histopathological analysis of renal specimen from
case 6. Light and electron microscopies of the renal specimen
from case 6. (a) Periodic acid Schiff (PAS) staining of typical
glomerulus and surrounding tubules of the renal specimen of
case 6 at 9 years of age (first biopsy). (b) Findings of the same case
at 11 years of age (second biopsy). This glomerulus shows typical
morphological changes compatible with focal segmental
glomerulosclerosis. (c) Electron microscopy of first biopsy
specimen shows a nearly normal appearance of the glomerular
basement membrane with focal podocyte foot process
effacement (arrow) and focal thickening of GBM (arrowhead).
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DISCUSSION
In this study, we showed that cases with MYH9 R702
mutation show a very rapid deterioration of renal function
with concurrent progressive hearing disability. Proteinuria
and/or hematuria was detected in early infancy, and ESRD
developed during adolescence. To date, several mutations
including S96L, R702C, R702H, R1165C, and D1424 have
been associated with the development of nephritis.7–10 Pecci
et al.9 showed that mutations in the motor domain of
NMMHC-IIA are associated with severe thrombocytopenia
and the development of nephritis and deafness before
40 years of age, whereas patients with mutations in the tail
domain not only have a much lower risk of developing
such impairments but also significantly higher platelet
counts. Heath et al.7 and Dong et al.8 described the
development of nephritis in patients with R702 mutations.
However, description of the clinical course of nephritis in
these reports was very limited. In this study, we examined the
precise clinical manifestations in nine patients with MYH9
R702 mutations, and showed a definite genotype–phenotype
correlation in both renal impairment and hearing
disability.
Figure 3 | Expression of NMMHC-IIA in the glomerulus from normal control and case 6 kidney samples. (a and b) NMMHC-IIA
expression in the glomerulus from normal control sample. NMMHC-IIA is strongly expressed in podocytes. (c and d) First biopsy specimen
from case 6. The intensity of immunostaining of NMMHC-IIA is already decreased. (e and f) Second biopsy specimen from case 6. The
intensity of immunostaining of NMMHC-IIA is decreased.
Figure 4 | Expression of NMMHC-IIA in normal control and case 6 kidney samples. (a–d) NMMHC-IIA expression in normal control
kidney sample. Compared with the strong staining of NMMHC-IIA in podocytes, its expression in other renal tissues is relatively weak. Weak
expression of NMMHC-IIA is observed in the distal nephron (b and d) and loop of Henle (b). Endothelial cells of arteries also express
NMMHC-HHA (c). In the first (e) and second (f) renal biopsy specimen from case 6, expression of NMMHC-IIA in tubular cells and
endocapillary cells is not remarkably changed compared with the controls, whereas decreased staining of podocytes is noted.
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In Epstein–Fechtner syndrome, renal biopsy is principally
contraindicated because of the accompanying thrombocyto-
penia. There have been few reports on the morphological
changes of renal histology in Epstein–Fechtner syndrome.
Only three reports on renal pathological findings are available
in the literature.13–15 Epstein et al.13 described the renal
morphology in a 13-year-old patient with Epstein syndrome.
Their study revealed interstitial fibrosis, focal mesangial
proliferation, and global sclerotic changes when the serum Cr
level was 0.6 mg/dl. A recent genetic study by Heath et al.7
identified MYH9 R702C mutation in this patient. Moxey-
Mims et al.14 performed renal biopsy twice in an African-
American female with Fechtner’s syndrome. The type of
MYH9 mutation in this patient was not identified in the
literature. The first biopsy at 7 years of age showed
proliferation of mesangial cells and matrix with alterations
in the GBM, such as effacement, thickening, and splitting; the
second biopsy at 10 years of age revealed global sclerotic
changes in 75% of glomeruli.14 Moxey-Mims et al.14 con-
cluded that these renal changes are similar to those in Alport
syndrome. Ghiggeri et al.15 performed renal biopsy in FTNS
patients with D1424H mutation, and electron microscopy
showed focal and segmental effacement of podocytes and loss
Control #1
Control #2
Control #3
Case4 Case5 Case6
Case9Case8Case7
Case1 Case2 Case3
Figure 5 |Distribution of NMMHC-IIA in the cytoplasm of neutrophils in control and cases with R702 mutations. Controls 1, 2, and 3:
Normal distribution of NMMHC-IIA in the cytoplasm of neutrophils. NMMHC-IIA is diffusely distributed in the cytoplasm. Cases 1 to 9:
In all the cases with MYH9 R702 mutations, NMMHC-IIA was condensed and localized in a granular pattern in the cytoplasm as indicated by
gray arrowheads.
Table 2 | Extrarenal manifestations in each patient
Type of cytoplasmic
Hearing disability
Case
no.
distribution of
NMMHC-IIA
Age of presentation
and severity
Latest
hearing level Cataract
1 II 2y2m: 50 db NT +
2 II () () ()
3 II () () ()
4 II 4y NT ()
5 II 4y 40–50 dB ()
6 II 8y10m: 30 dB 40–55 dB ()
7 II 10y 70–80 dB ()
8 II 9y Deaf ()
9 II 5y Deaf ()
Abbreviations: m, month; NMMHC-IIA, nonmuscle myosin heavy chain IIA; NT, not
tested; y, year.
Note: Abnormal distributions of NMMHC-IIA are classified into three types according
to the number, size, and shape of accumulated NMMHC-IIA granules (see also the
Materials and Methods section).16 Type II is characterized by the presence of up to
20 circular to oval NMMHC-IIA-positive spots (p1mm).
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of the interpodocyte slit diaphragm. The histopathological
changes reported so far could occur in various types of
glomerulonephritis. In this study, renal biopsy was per-
formed twice in case 6 with platelet transfusion. The second
renal biopsy specimen from case 6 showed that the
pathological diagnosis is FSGS. In Epstein–Fechtner’s syn-
drome with R702 mutation, progressive proteinuria and
rapid deterioration of renal function are the common
characteristics, as shown in this study, and the renal histology
in case 6 is compatible with the clinical features of
Epstein–Fechtner’s syndrome with MYH9 R702 mutation.
Epstein syndrome has been considered to be a variant of
Alport syndrome, because of their very similar phenotypes,
except for macrothrombocytopenic purpura, which is
observed only in Epstein syndrome. However, the following
two lines of evidence make them distinct from each
other. The first is the different types of urinary abnormality.
As shown in Table 1, proteinuria is equivalent or predomi-
nant in patients with Epstein syndrome; in contrast,
hematuria is predominant, and macroscopic hematuria is
often observed in patients with Alport syndrome much
earlier than proteinuria. The second is the differences in the
expression of causative genes in the glomeruli. The type IV
collagen a5 chain gene responsible for Alport syndrome
encodes an essential structural component of GBM; in
contrast, NMMHC-IIA encoded by MYH9 is exclusively
expressed in podocytes, renal tubular cells and endothelial
cells, as shown in Figure 3. In general, GBM abnormalities
could occur secondary to podocyte dysfunction. Taken
together, we consider that the alterations of GBM in Epstein
syndrome are a phenomenon secondary to the dysfunction
NMMHC-IIA molecule in podocytes owing to MYH9
mutation.
Kunishima et al.16 reported that the abnormal distribu-
tions of NMMHC-IIA in blood neutrophils in cases with
MYH9 disorders are classified into three types: type I,
NMMHC-IIA is condensed into one or two granular masses;
type II, NMMHC-IIA is present as granular masses of up to
20; type III, NMMHC-IIA is diffusely distributed as fine
granules throughout the cytoplasm. Kunishima et al.16 also
indicated that the type of abnormal distribution of
NMMHC-IIA is closely related to the site of the MYH9
mutation.16 In all the cases in this study, NMMHC-IIA
distribution in neutrophils was of type II (Figure 5 and
Table 2).
The abnormal distribution of NMMHC-IIA in Epstein–-
Fechtner syndrome could be directly associated with the
pathogenesis in the kidney. Arrondel et al.17 showed the
expression of NMMHC-IIA in podocytes, endocapillary cells,
and proximal tubular cells in the human kidney. In this study,
we show that NMMHC-IIA is expressed in the glomerulus,
tubular cells including the distal tubule, loop of Henle, and
the proximal tubule, endothelial cells of the interlobular
arteries and arterioles, and peritubular capillaries. Ghiggeri
et al.15 discussed that the aggregation and compartmentation
of NMMHC-IIA in podocytes might be associated with
podocin dysfunction. In addition, there is another possibility.
Two hereditary types of FSGS with an autosomal dominant
trait are known, and one is caused by mutations in the gene
encoding a-actinin-4 (ACTN4).18 Several studies have
indicated the following possible mechanisms: mutations in
ACTN4 increased the ability of binding of mutated a-actinin-
4 to actin filaments, alter their intracellular localization, and
finally cause FSGS.19,20 Michaud et al.20 showed that when
mutated a-actinin-4 is expressed in cultured podocytes, and
the localization of a-actinin-4 changes; that is, aberrant
sequestering of a-actinin-4 impairs podocyte spreading and
motility and decreases the number of peripheral projections.
They suggested that these cytoskeletal derangements may
underlie podocyte damage and foot process effacement.
Recently, several studies have indicated that NMMHC-II has
important roles in cell polarity, cell adhesion, and cell
migration.21 Podocytes are highly differentiated epithelial
cells, and are connected to each other through a specific
cell–cell adhesion molecule complex, that is, a slit diaphragm,
which is crucial for glomerular filtration. NMMHC-IIA is
considered to be located at the scaffolding underneath the
plasma membrane and in the cytoplasm, and to have a role in
maintaining and disassembling the adhesion junction com-
plex.21 It is plausible that mutated NMMHC-IIA would
impair the function and structure of the slit diaphragm,
which would result in proteinuria and the development
of FSGS.
It has been reported that human immunodeficiency virus-
related or hypertension-related FSGS are common in the
African-American populations. Recently, two groups have
independently identified a highly significant association
between the development of FSGS or ESRD and single-
nucleotide polymorphisms in MYH9 in African-American
individuals using an admixture-mapping linkage-disequili-
brium genome scan method.11,12 The development of ESRD
was associated with hypertension, not with diabetes mellitus.
This evidence strongly indicates that NMMHC-IIA is
responsible for the development of not only Epstein–Fechtner
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Figure 6 | Effect of valsartan on urinary protein excretion.
The effect of 20mg of valsartan on urinary protein excretion
(urine protein g/urine creatinine mg) in case 2 is shown.
The start of treatment with valsartan in case 6 was immediately
after the age of 3 years (y) and 4 months (m), when the urinary
protein level was nearly 0.7 g/g Cr.
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syndrome, but also idiopathic FSGS. There is no information
on why specific single-nucleotide polymorphisms in MYH9
increase the susceptibility of African-American individuals to
FSGS or ESRD. Clarification of the pathophysiological
mechanisms underlying the development of FSGS in
Epstein–Fechtner syndrome would provide clues elucidating
the molecular mechanisms underlying the development of
FSGS.
Just recently, Pecci et al.22 have reported a favorable effect
of ACEI and/or ARB on proteinuria in patients genetically
diagnosed with Epstein–Fechtner syndrome. In this study,
three cases among the nine enrolled were treated with ARB
and/or ACEI. In case 2, administration of 20 mg of valsartan
markedly reduced the amount of protein in the urine
(Figure 3). In cases 4 and 7, ARB and ACEI partially reduced
the amount of proteinuria. These findings, as well as those of
Pecci et al., suggest the protective effect of ARB and ACEI on
the kidney in cases with D1424H and N93K mutations. As
the susceptibility to ESRD or FSGS caused by certain single-
nucleotide polymorphisms in MYH9 in African Americans is
also associated with hypertension, ARB and ACEI presum-
ably showed a protective effect on the progression of renal
dysfunction owing to their direct effects on podocytes.
This is another important issue in the elucidation of the
mechanisms underlying the development of FSGS related to
NMMHC-IIA.
In conclusion, in this study, we showed a rapid
deterioration of renal function in cases with MYH9 R702
mutation, and the pathological findings in one case were
consistent with FSGS; apparent changes in NMMHC-IIA
expression in podocytes were observed in this patient.
Further studies are required to elucidate the possible
pathophysiological mechanisms by which podocyte dysfunc-
tion occurs because of R702 mutations in MYH9, which is
cardinal in the development of FSGS in African-American
populations. Such studies could provide us clues to the
mechanisms underlying the development of idiopathic FSGS.
MATERIALS AND METHODS
Cases
We performed genetic analysis in approximately 100 patients
suspected of having MYH9 disorders. Among those 100 patients,
we selected all unrelated patients with R702 mutation and enrolled
them in this study (Table 1). Some of the clinical and hematological
data of patients 1, 2, 4, and 5 were previously published:23 except for
case 4, there were no symptoms of nephritis in these patients
previously reported. The other cases are all new.
Details of clinical data and courses, the treatment for nephritis,
the treatment for ESRD, and the latest clinical data were obtained by
the attending physician in each case. Ocular abnormalities and
hearing disabilities were evaluated by ophthalmologists and
otolaryngologists, respectively.
The renal biopsy specimens from case 6 were evaluated by light
microscopy and electron microscopy using conventional techniques.
Immunohistochemical analysis was carried out as described below.
Genetic analysis of MYH9 was approved by the institutional
review boards of Nagoya Medical Center and each of the hospitals
where the patients were enrolled, and was performed after informed
consent was obtained from the patients and/or their parents. The
IRB of the National Hospital Organization Nagoya Medical Center
also approved the publication of the case reports and the obtained
experimental data. Mutational analysis of MYH9 was performed as
previously described.6
Immunohistochemical analysis of renal specimens from
control and case 6 kidney samples
Renal biopsy specimens from normal control and case 6 kidney
samples were also subjected to immunohistochemical analysis. This
was performed using 3 mm-thick sections of a paraffin-embedded
sample. A renal specimen derived from a 51-year-old renal
transplantation donor kidney, which was excised from the donor
with immediate perfusion (0 h), was used as a control. Each renal
section was autoclaved for 15 min at 121 1C in a citrate buffer of pH
6.0. After washing with water and phosphate-buffered saline, each
section was incubated with an anti-NMMHC-IIA antibody (BT561,
Biomedical Technologies, Stoughton, MA, USA, 1:100) for 2 h at
room temperature. After washing, each section was further
incubated with a secondary antibody (ENVISION, Dako, Kyoto,
Japan) for 20 min. Subsequently, each section was treated with
streptavidin-horseradish peroxidase and diaminobenzidine. The
sections were then counterstained with hematoxylin.
Immunofluorescence analysis of NMMHC-IIA in peripheral
blood neutrophils
Immunofluorescence analysis was performed to evaluate the
subcellular localization of NMMHC-IIA in peripheral blood
neutrophils as previously described.16 The cytoplasmic distribution
patterns of NMMHC-IIA in neutrophils can be classified according
to the number, size, and shape of accumulated NMMHC-IIA
granules, into types I, II, and III. Type I comprises one or two large
(0.5–2 mm), intensely stained, oval- to spindle-shaped cytoplasmic
NMMHC-IIA-positive granules. Type II comprises up to 20 circular
to oval cytoplasmic granules (p1 mm). Type III appears as a
speckled staining. The pattern of localization correlates with the site
of MYH9 mutation. Mutations in exons 16, 26, and 30 are associated
with type II localization.16
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